Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Abeona Therapeutics (ABEO) EBIT: 2011-2024

Historic EBIT for Abeona Therapeutics (ABEO) over the last 13 years, with Dec 2024 value amounting to -$64.2 million.

  • Abeona Therapeutics' EBIT fell 56.52% to -$24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.2 million, marking a year-over-year decrease of 36.97%. This contributed to the annual value of -$64.2 million for FY2024, which is 36.23% down from last year.
  • Per Abeona Therapeutics' latest filing, its EBIT stood at -$64.2 million for FY2024, which was down 36.23% from -$47.1 million recorded in FY2023.
  • In the past 5 years, Abeona Therapeutics' EBIT registered a high of -$47.1 million during FY2023, and its lowest value of -$89.8 million during FY2021.
  • Moreover, its 3-year median value for EBIT was -$50.9 million (2022), whereas its average is -$54.1 million.
  • As far as peak fluctuations go, Abeona Therapeutics' EBIT soared by 43.32% in 2022, and later plummeted by 36.23% in 2024.
  • Abeona Therapeutics' EBIT (Yearly) stood at -$81.4 million in 2020, then declined by 10.34% to -$89.8 million in 2021, then surged by 43.32% to -$50.9 million in 2022, then climbed by 7.42% to -$47.1 million in 2023, then crashed by 36.23% to -$64.2 million in 2024.